Mitlak B H, Nussbaum S R
Endocrine Unit, Massachusetts General Hospital, Boston.
Annu Rev Med. 1993;44:265-77. doi: 10.1146/annurev.me.44.020193.001405.
Osteoporotic bone fractures are a significant public health problem resulting in substantial morbidity and for those who suffer a hip fracture, a significant one-year mortality. Bone densitometry provides an important measure of fracture risk and the newer techniques are useful in the management of individuals with osteoporosis. Estrogen administration will preserve bone mass in postmenopausal women, and the optimal intake of calcium and vitamin D is being evaluated. Newer agents such as calcitonin and bisphosphonates may provide potent therapies for preventing bone loss. This review focuses on bone densitometry as a diagnostic tool and on the use of therapeutic agents for osteoporosis.
骨质疏松性骨折是一个重大的公共卫生问题,会导致严重的发病率,对于髋部骨折患者而言,还会导致较高的一年死亡率。骨密度测量提供了骨折风险的一项重要指标,而更新的技术在骨质疏松症患者的管理中很有用。给予雌激素可维持绝经后女性的骨量,目前正在评估钙和维生素D的最佳摄入量。降钙素和双膦酸盐等新型药物可能为预防骨质流失提供有效的治疗方法。本综述重点关注骨密度测量作为一种诊断工具以及治疗骨质疏松症药物的应用。